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Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) has a reported incidence of 1–2/100,000 person-years. It is estimated
that there are 5000 people with ALS in the UK at any one time; however, the true figure and geographical distribution,
are unknown. In this study, we describe the establishment of a population register for England, Wales, and Northern
Ireland and report-estimated incidence. Methods: People with a diagnosis of ALS given by a consultant neurologist and
whose postcode of residence is within England, Wales, or Northern Ireland were eligible. The catchment area was based
on six data contributors that had been participating since 2016. All centres included in this analysis were in England,
and therefore Wales and Northern Ireland are not included in this report. Crude age- and sex-specific incidence rates
were estimated using population census records for the relevant postcodes from Office of National Statistics census data.
These rates were standardized to the UK population structure using direct standardization. Results: There were 232 peo-
ple in the database with a date of diagnosis between 2017 and 2018, when missing data were imputed there were an esti-
mated 287–301 people. The denominator population of the catchment area is 7,251,845 according to 2011 UK census
data. Age- and sex-adjusted incidence for complete cases was 1.61/100,000 person-years (95% confidence interval 1.58,
1.63), and for imputed datasets was 2.072/100,000 person-years (95% CI 2.072, 2.073). Discussion: We found incidence
in this previously unreported area of the UK to be similar to other published estimates. As the MND Register for
England, Wales, and Northern Ireland grows we will update incidence estimates and report on further analyses.
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Introduction
Motor neuron disease, also known as amyotrophic
lateral sclerosis (ALS), is an adult-onset neurode-
generative disease affecting upper and lower motor
neurons. Estimated global incidence of ALS is
1–2/100,000 person years, due to geographical
variation the range of estimated incidence by sub-
continent is 1–3/100,000 person years (1–3). ALS
causes progressive weakness and paralysis, with
death from respiratory failure usually between 2
and 3 years after diagnosis, but clinical presenta-
tion and disease progression are highly variable
(4). There is currently no cure for ALS, although
riluzole and more recently in some countries,
edaravone are approved drugs that modestly
extend survival for some people (5,6). Since the
initial discovery that mutations in the SOD1 gene
can cause ALS, there has been considerable pro-
gress in the identification of genetic risk factors
(7). Despite these advances, disease etiology in the
majority of cases is not understood. Heritability
estimates are compatible with the possibility that
non-genetic factors such as stochastic biological
events in aging, environmental exposures or life-
style choices contribute to disease risk, but there is
no consensus on what these factors are (8).
Population registers collect information about
every person diagnosed with a given condition in a
defined geographical area, providing a source of
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representative data that can be used by researchers
and authorities responsible for healthcare funding
and organization (9).
ALS is highly variable in its presentation and
clinical course. Collection of population-level data
about the clinical features in ALS, including cogni-
tive impairment, has led to a greater understanding
of prognostic significance of phenotypic subgroups
of ALS (10,11). Data from several European
population registers have been used to create an
accurate disease progression model which has
helped inform care planning and communication
with patients about prognosis (4). Population
register data were used to show that a multistep
model of disease may be relevant to ALS etiology,
and to estimate the number of “steps” likely to be
involved (12–14). Information from population
registers has also been used to estimate the pro-
jected number of people with ALS in the future if
current population demographic trends persist, as
well as for modeling the potential effects of future
disease-modifying treatments (15,16).
Population-based datasets eliminate the inher-
ent ascertainment bias of intervention and case–
control studies based on referral cohorts (17), pro-
viding unbiased estimates of the effects of exposure
to risk factors associated with ALS (18).
Comparisons of clinical characteristics of patients
enrolled in drug trials and population-based data
from the same recruiting area show large differen-
ces that might help explain lack of generalisability
of results from intervention trials.
Some trends in ALS are consistently reported
between countries, for example, most people present
with symptoms in the limbs (19). However, the pheno-
typic spectrum differs between countries as shown by
studies quantifying incidence, peak age of onset of
symptoms, proportions of people with different sites of
presentation, and survival time (19,20). These differ-
ences are probably due to demographic and healthcare
factors, therefore, it is important to collect information
at a local level to inform patients and healthcare profes-
sionals. In the UK there are five regional population
registers for ALS: the South East ALS (SEALS)
Register, Peninsula Network, South Wales Register,
Northern Ireland register, and MND Care in
Scotland, as well as many long-standing databases that
document the attendees of specialist ALS clinics
(21–25). All have provided insight into the overall pic-
ture of ALS in the UK and have contributed to esti-
mates of UK-wide incidence, prevalence, and lifetime
risk. There are an estimated 5000 people living with
ALS in the UK at any one time, but whether this is the
true figure and how people with ALS are geographic-
ally distributed is not known.
In this paper, we describe the creation of the
MND Register for England, Wales, and Northern
Ireland through the incorporation of local popula-
tion registers, use of data collected routinely to
organize ALS clinics, and involvement of people
with ALS directly through a self-registration web-
site. We also report initial findings on incidence
for areas with complete case ascertainment.
Methods
Patient eligibility
Eligible individuals were defined as having been diag-
nosed with ALS, Primary Lateral Sclerosis (PLS), or
Progressive Muscular Atrophy (PMA) by a consult-
ant neurologist. Where motor neuron involvement
appeared to be restricted to the upper or lower motor
neurons (including flail limb variants), but time since
diagnosis was less than 4 years, the diagnostic cat-
egory was recorded as “upper motor neuron predom-
inant ALS” or “lower motor neuron predominant
ALS”, with a free text box available for provision of
more detail if needed. Site of onset of first focal
weakness, El Escorial category, and co-existing
dementia were considered as phenotypic modifiers
and recorded as separate variables (26). People with
cognitive impairment, including those with fronto-
temporal dementia were eligible. People with
Kennedy’s disease were not included.
People with ALS provided informed consent
for the inclusion of identifiable data in the register
to their healthcare professional or via our website
(details below). As an informed consent discussion
may not always be appropriate during a clinic
appointment, or progression may be so rapid as to
preclude an approach for informed consent, an
anonymised data capture protocol was devised.
Identifying data sources
It is estimated that 90% of people with ALS will
visit a specialist ALS service as part of their path-
way of care in the UK; many of these services are
funded in part by the ALS charity the Motor
Neurone Disease Association and are referred to
as MND Care and Research Centers or Networks
(90% figure from internal report from Motor Neurone
Disease Association). Therefore, we specifically
invited all of these services to contribute data. To
ensure complete case ascertainment, we identified
other services, including general neurology clinics,
community services, clinical nurse specialists, and
hospices where people with ALS also receive care.
Catchment areas
Specialist centres generally oversee a defined geo-
graphic area of the country. We asked each site to
identify the areas in which every incident case of
ALS would be referred to them to map areas of
complete ascertainment. This information was
generally provided in the form of UK postcode
districts (for example, SE22 or SE5), unitary
authorities, or counties. Many areas were
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overlapping between centres so cases were some-
times reported more than once.
Data collection and transfer
The project has been designed to avoid duplication
of data collection efforts for health professionals
and researchers. Where there was a local popula-
tion register or long-standing clinical database
already in use, the local dataset was aligned with
the agreed Register dataset. Where there was no
database in use we provided a Microsoft Access
template with data export functionality. There are
many pieces of information that are collected to
facilitate routine care organization and some of
these, such as postcode, name, hospital identifier,
and sex are also part of our dataset. The template
database was designed to be compatible with use
as part of routine care to avoid duplication of the
data collection effort. A minimum dataset of
name, date of birth, unique national health service
identifier, date of diagnosis, diagnosis (subtype of
ALS), date of first weakness, site of first weakness,
sex, and postcode of residence was requested to
ensure the ability to estimate incidence and iden-
tify duplicate records.
People with ALS in the UK will encounter a
variety of services, including tertiary referral
centres, general neurology clinics, general practi-
tioners, clinical nurse specialists, and local therapy
teams. ALS is a clinical diagnosis which needs to
be monitored over time, and people often see
more than one consultant neurologist to confirm
the diagnosis. As a consequence, duplicate records
could be generated for the same patient by differ-
ent data contributors. We used pseudonymisation
to differentiate duplicate records while maintaining
confidentiality of participants.
Website for patient self-registration
A website was developed to allow people living
with MND to self-register for inclusion in the
database and to provide consent for access to their
clinical information (https://mndregister.ac.uk)
with the aim of increasing direct patient participa-
tion and case ascertainment. At registration, par-
ticipants were asked to indicate the neurologist
who provided their diagnosis or ongoing care, to
facilitate confirmation of clinical details from the
medical record.
Statistical analysis
Data were extracted from local databases between
September and October 2019 The data included
complete records from people who had provided
consent, as well as de-identified records from indi-
viduals who could not be approached for
informed consent.
We used disease diagnosis to estimate inci-
dence, focusing on the years 2017 and 2018 to
include the most complete dataset based on avail-
able records.
Patients were grouped by age at diagnosis and
sex in five-year age bands. We had an open-ended
cohort for individuals over 85 years at the time of
disease diagnosis, so these cases were analyzed
together. Crude age-and sex-specific incidence
rates were estimated using age- and sex-specific
2011 population census records for the relevant
postcodes from Office of National Statistics (ONS)
census data, the estimates are reported in person-
years (27). These rates were standardized to the
UK population structure as measured by the 2011
UK census, the US population structure as meas-
ured by the US 2010 census and the European
standard population using the direct standardiza-
tion method (28–31). We received residential data
from people who had not provided consent for
transfer of identifiable data at postcode area level
(e.g. SE) to ensure anonymity. Our denominator
population was made up of postcode areas where
we had 100% capture, which was a subset of our
total catchment area (darker gray areas in
Figure 1).
Confidence intervals for crude rates were esti-
mated using the exact method for Poisson intervals
(32). Confidence intervals for overall age- and sex-
adjusted incidence rates were estimated at the
95% level using an approximation of the standard
error for a binomial proportion (33).
Multiple imputation
To impute diagnostic delay we used predictive
mean matching to generate 22 datasets (as 22% of
cases were missing diagnostic delay) and calculated
incidence for all datasets (34,35). The model for
predictive mean matching included data collection
center, age of onset, gender, diagnosis subtype,
site of onset, and family history. We pooled esti-
mates of incidence and 95% confidence intervals
using Rubin’s rules (36). Imputated datasets were
generated using the R package “mice” (37,38).
Results
We defined an area of complete data capture by
combining the catchment areas of six data collec-
tion centres that had been participating continu-
ously since 2016. The complete postcode area for
the catchment zone, the denominator population,
represents a population of over seven million peo-
ple and is indicated by the darker gray areas in
Figure 1.
As of October 2019, there were 5066 records
in the MND Register, through data transfers from
17 centres, including 426 people who had signed
up online. We extracted data based on postcode
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area of residence at diagnosis. After data cleaning
there were 1748 records, of these, 232 recorded a
date of diagnosis between 2017 and 2018, referred
to as the complete case dataset. 312 people had no
date of diagnosis recorded, but all had a date of
onset. We used imputed values of diagnostic delay
to estimate date of diagnosis (Figure 2).
The casemix of the complete case dataset is
shown in Table 1.
Counts of people in the catchment area by age
and sex (from the complete case dataset) are
reported in Table 2.
After multiple imputation, estimated numbers
of people diagnosed between 2017 and 2018
ranged from 287 to 301. The pooled and complete
case incidence estimates are presented in Table 3.
The estimated age- and sex-adjusted incidence for
the UK is 1.61/100,000 (95% confidence interval
1.58, 1.63) based on complete case analysis and
2.07/100,000 (95% CI 2.072, 2.073) people based
on the imputed dataset.
Discussion
We have established a population register that
identifies records from multiple sources and uses
data that are often available as part of routine data
collection for care. The base population for our
incidence calculation is over seven million people
and therefore represents a large register compared
to others globally. Once the MND Register
includes data from all areas of the UK, which is
the aim of the project, it will represent a database
of a scale not yet reported. There are significant
challenges in organizing and maintaining a data-
base for a population this size, including the co-
ordination of data collection across independent
hospital systems.
Figure 1. Map of catchment areas of each clinic in light grey, with the whole postcode areas shaded in darker grey.
Figure 2. Flow chart detailing inclusion of cases from the database.
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Organizing a population register as a federated
database can result in selection bias because of
boundary effects. Through annexation of areas of
complete ascertainment over time, it will provide a
more complete, unbiased picture of the disease.
Although the catchment area is constructed from
six centres, extracting data by postcode of resi-
dence meant including data from eight centres
rather than six, 25 cases were transferred by the
two extra centres.
UK geography is organized into many partially
overlapping administrative units. Postcode is ubi-
quitously recorded but hospital catchment areas
and population estimates are made up of county
or unitary authority boundaries that are not always
congruent with postcodes. This and the transfer of
anonymised data that includes high-level postcode
rather than the full postcode data has made esti-
mating incidence challenging while there are few
centres participating. This is expected to improve
as the MND Register includes more data contribu-
tors over time. Our study is part of the UK
Clinical Research Network, so other services not
included in this mapping effort will potentially be
notified of the project and be incentivised to par-
ticipate. The MND Register team regularly attends
Table 1. Basic demographics and clinical features of people with ALS, complete cases and by sex.
Variable Total 5 232 Female Male





106 (45.7) 91 (91) 107 (82)
Lower motor neuron
predominant ALS
8 (3.4) 2 (2) 6 (4.6)
Upper motor neuron
predominant ALS
8 (3.4) 2 (2) 6 (4.6)
Primary lateral sclerosis 7 (3.01) 2 (2) 5 (3.9)
Progressive
muscular atrophy
3 (1.3) 3 (3) 0 (0)
Site of onset
N (%)
Bulbar 67 (28.9) 42 (42) 25 (19.2)
Spinal 118 (50.9) 41 (41) 76 (58.5)
Respiratory 6 (2.6) 2 (2) 4 (3.01)
Generalised 13 (5.6) 5 (5) 8 (6.2)
Not recorded 28 (12.1) 10 (10) 17 (13.1)
Mean age of onset (SD) 64 (12)
27 records missing data
67 (12)
13 records missing data
62 (12)
13 records missing data
Table 2. Population counts for men and women in each age group.
Overall Female Male
n Local population n Local population n Local population
16–44 16 3507543 5 1746724 21 1760819
45–49 8 664362 3 334775 5 329587
50–54 17 572399 7 286996 10 285403
55–59 32 498531 8 252548 23 245983
60–64 31 530802 13 271113 18 259689
65–69 31 423035 14 217876 17 205159
70–74 41 339173 16 177671 24 161502
75–79 25 281413 13 153323 12 128090
80þ 31 434587 21 272241 10 162346
Ages 16–44 are shown as one category but were analyzed in 5-year age bands (except 16–19 which was 4 years).
Ages 80–84 85þ were also analyzed separately but are displayed in aggregate. The local population numbers
were multiplied by 2 to calculate person-years.
Table 3. Incidence calculations for men and women separately, standardized to different reference populations.
Overall Female Male
Complete case analysis England, Wales and Northern Ireland 1.61 (1.58, 1.63) 1.35 (1.31, 1.38) 1.85 (1.8, 1.9)
European standard 1.76 (1.73, 1.78) 1.41 (1.37, 1.45) 2.07 (2, 2.13)
US 2010 census 1.45 (1.43, 1.47) 1.21 (1.18, 1.24) 1.67 (1.63, 1.71)
Imputed England, Wales and Northern Ireland 2.072 (2.072, 2.073) 1.775 (1.774, 1.777) 2.356 (2.353, 2.359)
European standard 2.267 (2.266, 2.268) 1.874 (1.872, 1.876) 2.63 (2.626, 2.635)
US 2010 census 1.874 (1.873, 1.874) 1.59 (1.589, 1.591) 2.133 (2.13, 2.135)
Imputed rates are shown to three decimal places to reflect the accuracy needed to display the pooled 95% confidence intervals.
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symposia and local conferences, and use social
media in order to raise awareness about the pro-
ject, including the self-registration website. There
are regular campaign efforts from the MND
Association including a spread about the Register
in their quarterly magazine and videos to help peo-
ple self-register.
The advantages of collecting clinical data from
already existing databases are that it reduces bur-
den on healthcare professionals who may have to
collect similar data for a range of different report-
ing processes and care tasks, and is relatively inex-
pensive. It is a system that is successfully used by
other population registers in the UK. The disad-
vantages are that there is less control over the for-
mat of data collected and it cannot be easily
modified to incorporate other data collection.
Although centralized databases have worked suc-
cessfully in smaller areas such as Scotland and
Northern Ireland, the scale of NHS services in
England and Wales mean this is unlikely to be
possible at present. Through establishment of con-
tributing centres in many different locations
throughout England, Wales, and Northern Ireland
we have encountered variation in care proc-
esses locally.
The National Amyotrophic Lateral Sclerosis
Registry in the US and the TREAT-NMD neuro-
muscular network utilize patient-reported data
(39,40). In addition, the US Registry collects clin-
ical data from administrative datasets, a method
we plan to use to supplement data collection in
the future. Analysis of case ascertainment of the
US Registry shows variation by race and insurance
use (41). We may not be counting privately treated
patients who prefer not to register online, although
this is expected to be a small number of people as
NHS services provide high-quality multidisciplin-
ary care.
Using this new register, we have estimated the
incidence of ALS for previously unreported areas
of England. We estimate that age- and sex-
adjusted UK incidence is 1.61/100,000 person-
years and 2.07/100,000 person-years using
imputed data. The comparison of rates will focus
on the imputed incidence because it is less likely
to be an under-estimate. The imputed estimated
incidence is slightly lower than reported in some
smaller population registers in the UK, for
example the rate of 2.52/100,000 in Devon and
Cornwall, 2.1/100,000 in the South East ALS
Register, and higher than 1.76/100,000 reported in
Lancashire (16,24,25).
Standardizing incidence to the European stand-
ard population resulted in an estimate of 2.26/
100,000 person-years, higher than the estimate of
1.4/100,000 reported in Northern Ireland (22).
Our imputed incidence standardized to the US
population is lower at 1.87/100,000 person-years,
which comparable to the 1.89/100,000 person
years reported for Northern Europe in 2017, but
lower than 3.83/100,000 person-years reported in
Scotland (2,42).
The EURALS consortium reported average
crude incidence rate of 2.16/100,000 person-years,
while the crude rate in this study 2.06/100,000
person-years (43). Our crude imputed incidence
rate is between the 2.40 and 1.49/100,000 person-
years reported for Northern and Southern Europe
in a recent global incidence study (3).
Our estimates are based on data from areas
that have not been sampled before, so the results
may reflect true lower incidence in these parts of
the UK. It is also possible that there are areas of
low case ascertainment in our sample. The MND
Register as a federated database is relatively new,
and the collection of data was initiated at different
times by individual participating sites. Detailed
reporting by population register in the Republic of
Ireland and Scotland have shown that data quality
and ascertainment improves over time (42,44,45).
As more centres contribute data, we will be able to
perform capture-recapture analysis of overlapping
areas allowing more accurate incidence estimates.
In the future we will estimate prevalence and
lifetime risk, as well as mapping incidence com-
pared to healthcare provision. Collecting large,
national datasets has helped improve care and
understanding of other diseases and we have laid
the groundwork and generated the momentum to
do this for ALS as well.
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